Equity Profile

CGON

CG Oncology, Inc.

Health CareBiotechnology$5.5B

May8Fri

Post-Earnings Recap

ReportedQ1-2026Pre-Market8:30 AM EDT

CG Oncology Misses on EPS, Stock Up 0.00%

Metric	Actual	Expected	Surprise
EPS	$-0.71	$-0.54	-23.26%
Revenue	$0M	$0M	N/A

management commentary, guidance changes, and full analysis available with Pro.

CG Oncology Misses on EPS, Stock Up 0.00%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.71	$-0.54	-23.26%
Revenue	$0M	$0M	N/A

Management Commentary

Tone: Unknown

No transcript is on record for the earnings call, and the analysis is based solely on numerical results.

What It Means

CG Oncology reported a larger-than-expected loss per share, which may raise concerns among investors about the company's financial health. Despite the miss on EPS, the stock showed no movement, indicating that investors may have anticipated the results. The lack of revenue and guidance adds uncertainty about the company's future performance.

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative treatments for cancer....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-0.54

Revenue

Revenue figures will provide insight into the company's market traction and product acceptance.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative treatments for cancer. Operating in the health care sector, it aims to address significant unmet medical needs in oncology, making its advancements crucial for patients and the broader medical community.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-28.85%

Avg Stock Reaction

+0.62%

Last Quarter Recap

In Q4-2025, CG Oncology reported an EPS of $-2.08, significantly missing analyst expectations. The stock reacted positively the following day, gaining 4.79%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect CG Oncology to report a loss of $-0.54 per share for Q1-2026, with no revenue anticipated. The market is cautious given the company's recent performance.

Bull Case

If CG Oncology can exceed expectations on EPS and show signs of revenue generation, it could signal a turnaround, attracting more investor interest.

Bear Case

A larger-than-expected loss or continued lack of revenue could lead to further declines in stock price, as investor confidence may wane.

Key Metrics to Watch

EPS

$-0.54

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$0M

Revenue figures will provide insight into the company's market traction and product acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CG Oncology's EPS come in better than the consensus estimate of $-0.54?

A smaller loss than expected could indicate improving operational efficiency and boost investor confidence.

Is there any indication of revenue generation this quarter?

Any revenue, even if minimal, would be a positive sign of product acceptance and market traction.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate CG Oncology's potential for cost management and operational improvements, which could lead to better-than-expected EPS results.

Supporting Evidence

The stock has shown resilience in past quarters despite misses, indicating potential for recovery.

Options pricing suggests a significant move, which may reflect underlying investor optimism not captured in consensus estimates.

Key Risk

If the EPS loss is significantly lower than $-0.54, it could challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching CG Oncology's ability to manage losses and generate revenue, which will significantly influence investor sentiment.

Bull Confirmed If

A reported EPS loss of less than $-0.54 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.54 would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±11.69%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±11.5% while CGON has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

45.0%

Calls (9K)P/C Ratio: 0.26Puts (10K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.1M

15,600 sh

1 insider

Net

$1.1M

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CG Oncology beats EPS estimates, history suggests the stock could rise by around 0.10%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future performance.

Miss

Should the company miss expectations, the stock could drop by approximately 0.83%, indicating ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on potential revenue generation from new treatments.
2Management's commentary on cost management strategies and operational efficiency.
3Insights into ongoing clinical trials and their expected timelines.
4Any guidance on future earnings expectations or product launches.
5Reactions to competitive landscape changes in the oncology market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May5

EXPDReported

Expeditors International of Washington, Inc.

RecapView

May5

IRONReported

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative treatments for cancer....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-0.54

Revenue

Revenue figures will provide insight into the company's market traction and product acceptance.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-28.85%

Avg Stock Reaction

+0.62%

Last Quarter Recap

In Q4-2025, CG Oncology reported an EPS of $-2.08, significantly missing analyst expectations. The stock reacted positively the following day, gaining 4.79%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect CG Oncology to report a loss of $-0.54 per share for Q1-2026, with no revenue anticipated. The market is cautious given the company's recent performance.

Bull Case

If CG Oncology can exceed expectations on EPS and show signs of revenue generation, it could signal a turnaround, attracting more investor interest.

Bear Case

A larger-than-expected loss or continued lack of revenue could lead to further declines in stock price, as investor confidence may wane.

Key Metrics to Watch

EPS

$-0.54

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$0M

Revenue figures will provide insight into the company's market traction and product acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CG Oncology's EPS come in better than the consensus estimate of $-0.54?

A smaller loss than expected could indicate improving operational efficiency and boost investor confidence.

Is there any indication of revenue generation this quarter?

Any revenue, even if minimal, would be a positive sign of product acceptance and market traction.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate CG Oncology's potential for cost management and operational improvements, which could lead to better-than-expected EPS results.

Supporting Evidence

The stock has shown resilience in past quarters despite misses, indicating potential for recovery.

Options pricing suggests a significant move, which may reflect underlying investor optimism not captured in consensus estimates.

Key Risk

If the EPS loss is significantly lower than $-0.54, it could challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching CG Oncology's ability to manage losses and generate revenue, which will significantly influence investor sentiment.

Bull Confirmed If

A reported EPS loss of less than $-0.54 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.54 would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±11.69%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±11.5% while CGON has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

45.0%

Calls (9K)P/C Ratio: 0.26Puts (10K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.1M

15,600 sh

1 insider

Net

$1.1M

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CG Oncology beats EPS estimates, history suggests the stock could rise by around 0.10%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future performance.

Miss

Should the company miss expectations, the stock could drop by approximately 0.83%, indicating ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on potential revenue generation from new treatments.
2Management's commentary on cost management strategies and operational efficiency.
3Insights into ongoing clinical trials and their expected timelines.
4Any guidance on future earnings expectations or product launches.
5Reactions to competitive landscape changes in the oncology market.